Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)
Spain flag Spain · Delayed Price · Currency is EUR
61.40
+0.45 (0.74%)
Dec 20, 2024, 5:35 PM CET

BME: ROVI Statistics

Total Valuation

Laboratorios Farmaceuticos Rovi has a market cap or net worth of EUR 3.14 billion. The enterprise value is 3.26 billion.

Market Cap 3.14B
Enterprise Value 3.26B

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date Feb 21, 2025
Ex-Dividend Date Jul 8, 2024

Share Statistics

Laboratorios Farmaceuticos Rovi has 51.15 million shares outstanding.

Current Share Class n/a
Shares Outstanding 51.15M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) n/a
Owned by Institutions (%) 21.62%
Float 18.61M

Valuation Ratios

The trailing PE ratio is 19.86 and the forward PE ratio is 18.56. Laboratorios Farmaceuticos Rovi's PEG ratio is 1.69.

PE Ratio 19.86
Forward PE 18.56
PS Ratio 4.10
PB Ratio 5.97
P/TBV Ratio 6.09
P/FCF Ratio 47.69
P/OCF Ratio n/a
PEG Ratio 1.69
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.66, with an EV/FCF ratio of 49.51.

EV / Earnings 19.76
EV / Sales 4.08
EV / EBITDA 13.66
EV / EBIT 15.35
EV / FCF 49.51

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.23.

Current Ratio 2.50
Quick Ratio 0.92
Debt / Equity 0.23
Debt / EBITDA 0.54
Debt / FCF 1.95
Interest Coverage 69.72

Financial Efficiency

Return on equity (ROE) is 29.65% and return on invested capital (ROIC) is 20.37%.

Return on Equity (ROE) 29.65%
Return on Assets (ROA) 15.55%
Return on Capital (ROIC) 20.37%
Revenue Per Employee 378,611
Profits Per Employee 78,162
Employee Count 2,111
Asset Turnover 0.94
Inventory Turnover 0.87

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +6.69% in the last 52 weeks. The beta is 0.51, so Laboratorios Farmaceuticos Rovi's price volatility has been lower than the market average.

Beta (5Y) 0.51
52-Week Price Change +6.69%
50-Day Moving Average 68.07
200-Day Moving Average 78.11
Relative Strength Index (RSI) 36.52
Average Volume (20 Days) 68,362

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of EUR 799.25 million and earned 165.00 million in profits. Earnings per share was 3.09.

Revenue 799.25M
Gross Profit 488.92M
Operating Income 212.57M
Pretax Income 211.73M
Net Income 165.00M
EBITDA 233.89M
EBIT 212.57M
Earnings Per Share (EPS) 3.09
Full Income Statement

Balance Sheet

The company has 17.55 million in cash and 128.28 million in debt, giving a net cash position of -110.72 million or -2.16 per share.

Cash & Cash Equivalents 17.55M
Total Debt 128.28M
Net Cash -110.72M
Net Cash Per Share -2.16
Equity (Book Value) 558.19M
Book Value Per Share 10.28
Working Capital 332.34M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 126.18 million and capital expenditures -60.32 million, giving a free cash flow of 65.86 million.

Operating Cash Flow 126.18M
Capital Expenditures -60.32M
Free Cash Flow 65.86M
FCF Per Share 1.29
Full Cash Flow Statement

Margins

Gross margin is 61.17%, with operating and profit margins of 26.60% and 20.64%.

Gross Margin 61.17%
Operating Margin 26.60%
Pretax Margin 26.49%
Profit Margin 20.64%
EBITDA Margin 29.26%
EBIT Margin 26.60%
FCF Margin 8.24%

Dividends & Yields

This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 1.80%.

Dividend Per Share 1.10
Dividend Yield 1.80%
Dividend Growth (YoY) -14.69%
Years of Dividend Growth 4
Payout Ratio 34.21%
Buyback Yield n/a
Shareholder Yield 1.80%
Earnings Yield 5.03%
FCF Yield 2.10%
Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Laboratorios Farmaceuticos Rovi has an Altman Z-Score of 9.95.

Altman Z-Score 9.95
Piotroski F-Score n/a